Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas
Cargando...
Archivos
Fecha
2023-01
Autores
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
MDPI
Nombre de Curso
Licencia CC
CC BY 4.0 DEED
Attribution 4.0 International
CC BY 4.0 DEED Attribution 4.0 International
CC BY 4.0 DEED Attribution 4.0 International
Licencia CC
https://creativecommons.org/licenses/by/4.0/
Resumen
The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.
Notas
Indexación: Scopus.
Palabras clave
Cancer therapy, Chemokines, Immunotherapy, Oncology
Citación
International Journal of Molecular Sciences, Open Access, Volume 24, Issue 1January 2023 Article number 478
DOI
10.3390/ijms24010478